Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

Bruce D. Cheson, Peter L. Greenberg, John M. Bennett, Bob Lowenberg, Pierre W. Wijermans, Stephen D. Nimer, Antonio Pinto, Miloslav Beran, Theo M. De Witte, Richard M. Stone, Moshe Mittelman, Guillermo F. Sanz, Steven D. Gore, Charles A. Schiffer, Hagop Kantarjian

Research output: Contribution to journalReview articlepeer-review

981 Scopus citations

Abstract

The myelodysplastic syndromes (MDSs) are heterogeneous with respect to clinical characteristics, pathologic features, and cytogenetic abnormalities. This heterogeneity is a challenge for evaluating response to treatment. Therapeutic trials in MDS have used various criteria to assess results, making cross-study comparisons problematic. In 2000, an International Working Group (IWG) proposed standardized response criteria for evaluating clinically significant responses in MDS. These criteria included measures of alteration in the natural history of disease, hematologic improvement, cytogenetic response, and improvement in health-related quality of life. The relevance of the response criteria has now been validated prospectively in MDS clinical trials, and they have gained acceptance in research studies and in clinical practice. Because limitations of the IWG criteria have surfaced, based on practical and reported experience, some modifications were warranted. In this report, we present recommendations for revisions of some of the initial criteria.

Original languageEnglish (US)
Pages (from-to)419-425
Number of pages7
JournalBlood
Volume108
Issue number2
DOIs
StatePublished - Jul 15 2006
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia'. Together they form a unique fingerprint.

Cite this